Challenges and opportunities of allogeneic donorderived CAR T cells

Current Opinion in Hematology

Volumn 22, Issue 6, 2015, Pages 509-515

  Yang, Yinmeng ^a,b   Jacoby, Elad ^a   Fry, Terry J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

Adoptive immunotherapy; Allogeneic hematopoietic stem cell transplantation; Chimeric antigen receptors; Donor derived; Graft versus host disease

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; T LYMPHOCYTE RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER IMMUNOTHERAPY; CELL SELECTION; CELLULAR IMMUNITY; GENETIC ENGINEERING; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOBIOLOGY; INTRACELLULAR SIGNALING; MEMORY T LYMPHOCYTE; NONHUMAN; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; ALLOTRANSPLANTATION; DONOR SELECTION; IMMUNOLOGY; IMMUNOTHERAPY; T LYMPHOCYTE; TRANSPLANTATION;

DONOR SELECTION; GRAFT VS HOST DISEASE; HUMANS; IMMUNOTHERAPY; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 84944079434     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0000000000000181     Document Type: Review

References (76)

1. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versushost disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979; 300:1068-1073.
2. Thomas ED, Sanders J, Flournoy N, et al. Marrow transplantation lymphoblastic for leukemia patients with in remission. Blood 1979; 54:468-477.
3. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75:555-562.
4. Collins RH, Shpilberg O, Drobyski W, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15:433-444.
5. Schmid C, Labopin M, Nagler A, et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: A retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukem. J Clin Oncol 2007.
6. Levine JE, Barrett AJ, Zhang M-J, et al. Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric population. Bone Marrow Transplant 2008; 42:201-205.
7. Poon LM, Hamdi A, Saliba R, et al. Outcomes of adults with acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2013; 19:1059-1064.
8. Spyridonidis a, Labopin M, Schmid C, et al. Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT. Leukemia 2012; 26:1211-1217.
9. Gaynon PS, Harris RE, Altman AJ, et al. Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group study CCG- 1941. J Clin Oncol 2006; 24:3150-3156.
10. Blazar B, Murphy W, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol 2012; 12:443-458.
11. Sadelain M, Brentjens R, Riviè re I. The basic principles of chimeric antigen receptor design. Cancer Discov 2013; 3:388-398.
12. Mackall CL, Merchant MS, Fry TJ. Immune-based therapies for childhood cancer. Nat Rev Clin Oncol 2014; 11:693-703.
13. Maus MV, Grupp Sa, Porter DL, June CH. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 2014; 123:2625- 2635.
14. Kochenderfer JN, Yu Z, Frasheri D, et al. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood 2010; 116:3875-3886.
15. Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365:725-733.
16. Grupp Sa, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013; 368:1509-1518.
17. Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014; 6:224ra25.
18. Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial. Lancet 2014; 6736:1-12.
19. Maude SL, Frey N, Shaw Pa, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014; 371:1507- 1517.
20. Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2014; 33:540-549.
21. Fry TJ, Mackall CL. Immune reconstitution following hematopoietic progenitor cell transplantation: challenges for the future. Bone Marrow Transplant 2005; 35 (Suppl 1):S53-S67.
22. Capitini CM, Herby S, Milliron M, et al. Bone marrow deficient in IFN-{gamma} signaling selectively reverses GVHD-associated immunosuppression and enhances a tumor-specific GVT effect. Blood 2009; 113:5002-5009.
23. Capitini CM, Nasholm NM, Duncan BB, et al. Graft-versus-host disease impairs vaccine responses through decreased CD4 and CD8 T cell proliferation and increased perforin-mediated CD8 T cell apoptosis. J Immunol 2013; 190:1351-1359.
24. Meunier M, Roy-Proulx G, Labrecque N, Perreault C. Tissue distribution of target antigen has a decisive influence on the outcome of adoptive cancer immunotherapy. Blood 2003; 101:766-770.
25. Shand JC, Qin H, Nasholm N, et al. Minor antigen distribution predicts sitespecific graft-versus-tumor activity of adoptively transferred, minor antigenspecific CD8 T Cells. Biol Blood Marrow Transplant 2014; 20:26-36.
26. Alcantar-Orozco EM, Gornall H, Baldan V, et al. Potential limitations of the NSG humanized mouse as a model system to optimize engineered human T cell therapy for cancer. Hum Gene Ther Methods 2013; 24:310-320.
27. Chan WK, Suwannasaen D, Throm RE, et al. Chimeric antigen receptorredirected CD45RA-negative T cells have potent antileukemia and pathogen memory response without graft-versus-host activity. Leukemia 2015; 29:387-395.
28. Marcus A, Waks T, Eshhar Z. Redirected tumor-specific allogeneic T cells for universal treatment of cancer. Blood 2011; 118:975-984.
29. Kochenderfer JN, Dudley ME, Carpenter RO, et al. Donor-derived CD19- Targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 2013; 122:4129-4139.
30. Rossig C, Bollard C, Nuchtern J. Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood 2002; 99:2009-2017.
31. Leen AM, Myers GD, Sili U, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006; 12:1160-1166.
32. Hanley P, Shaffer D, Cruz C, et al. Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein-Barr virus and adenovirus to provide broad antiviral specificity after stem cell. Cytotherapy 2011; 13:976- 986.
33. Leen AM, Bollard CM, Mendizabal AM, et al. Multicenter study of banked thirdparty virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood 2013; 121:5113-5123.
34. Savoldo B, Rooney C, Di Stasi A, et al. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood 2007; 110:1-3.
35. Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells enginerred to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2009; 14:1264-1270.
36. Terakura S, Yamamoto TN, Gardner RA, et al. Generation of CD19-chimeric antigen receptor modified CD8 T cells derived from virus-specific central memory T cells. Blood 2012; 119:72-82.
37. Sun J, Huye LE, Lapteva N, et al. Early transduction produces highly functional chimeric antigen receptor-modified virus-specific T-cells with central memory markers: A Production Assistant for Cell Therapy (PACT) translational application. J Immunother Cancer 2015; 3:1-17.
38. Cruz CRY, Micklethwaite KP, Savoldo B, et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: A phase 1 study. Blood 2013; 122:2965- 2973.
39. Kebriaei P, Huls H, Singh H, et al. Adoptive therapy using sleeping beauty gene transfer system and artificial antigen presenting cells to manufacture T cells expressing CD19-specific chimeric antigen receptor. Blood 2014; 124:311-1311.
40. Weijtens ME, Hart EH, Bolhuis RL. Functional balance between T cell chimeric receptor density and tumor associated antigen density: CTL mediated cytolysis and lymphokine production. Gene Ther 2000; 7:35-42.
41. Labrecque N, Whitfield LS, Obst R, et al. How much TCR does a T cell need? Immunity 2001; 15:71-82.
42. James SE, Greenberg PD, Jensen MC, et al. Mathematical modeling of chimeric TCR triggering predicts the magnitude of target lysis and its impairment by TCR downmodulation. J Immunol 2010; 184:4284-4294.
43. Watanabe K, Terakura S, Martens aC, et al. Target antigen density governs the efficacy of anti-CD20-CD28-CD3 chimeric antigen receptor-modified effector CD8 T cells. J Immunol 2014; 194:911-920.
44. Love PE, Lee J, Shores EW. Critical relationship between TCR signaling potential and TCR affinity during thymocyte selection. J Immunol 2000; 165:3080-3087.
45. Pauza M, Smith KM, Neal H, et al. Transgenic expression of Ly-49A in thymocytes alters repertoire selection. J Immunol 2000; 164:884-892.
46. Palmer E, Naeher D. Affinity threshold for thymic selection through a T-cell receptor-co-receptor zipper. Nat Rev Immunol 2009; 9:207-213.
47. Oren R, Hod-Marco M, Haus-Cohen M, et al. Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds. J Immunol 2014; 193:5733-5743.
48. Cooper LJN. Off-the-shelf T-cell therapy. Blood 2010; 116:4741-4743.
49. Yanagisawa M, Ngo M, Rooney CM, et al. Using viruses to advance T cell therapy for malignancy [abstract]. In: Proceedings of the AACR Special Conference on Tumor Immunology: Multidisciplinary Science Driving Basic and Clinical Advances; Dec 2-5, 2012; Miami, FL. Philadelphia (PA): AACR. Cancer Res 2013; 73 (1 Suppl):Abstract nr IA21.
50. Anderson B, McNiff J, Yan J. Memory CD4 T cells do not induce graftversus- host disease. J Clin Investig 2003; 112:101-108.
51. Chen BJ, Cui X, Sempowski GD, et al. Transfer of allogeneic CD62L-memory T cells without graft-versus-host disease. Blood 2004; 103:1534-1541.
52. Foster A, Marangolo M, Sartor M. CD62L-memory T cells are less responsive to alloantigen stimulation than CD62L naive T cells: potential for adoptive immunotherapy and allodepletion. Blood 2004; 104:2403-2410.
53. Kondo M, Sakuta K, Noguchi A, Ariyoshi N. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy. Cytotherapy 2008; 10:842-856.
54. Deniger DC, Switzer K, Mi T, et al. Bispecific T-cells expressing polyclonal repertoire of endogenous gd T-cell receptors and introduced CD19-specific chimeric antigen receptor. Mol Ther 2013; 21:638-647.
55. Themeli M, Kloss CC, Ciriello G, et al. Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat Biotechnol 2013; 31:928-933.
56. Rei M, Pennington DJ, Silva-Santos B. The emerging Protumor role of gd T lymphocytes: implications for cancer immunotherapy. Cancer Res 2015; 75:798-802.
57. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295:2097-2101.
58. Bachanova V, Cooley S, Defor TE, et al. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood 2014; 123:3855-3863.
59. Rubnitz J, Inaba H, Kang G, et al. Natural killer cell therapy in children with relapsed leukemia. Pediatric Blood Cancer 2015; 62:1468-1472.
60. Shah NN, Baird K, Delbrook CP, et al. Acute GVHD in patients receiving IL- 15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation. Blood 2015; 125:784-792.
61. Chu Y, Hochberg J, Yahr A, et al. Targeting CD20 aggressive B-cell non-Hodgkin lymphoma by anti-CD20 CAR mRNA-modified expanded natural killer cells in vitro and in NSG mice. Cancer Immunol Res 2015; 3:333- 344.
62. Heczey A, Liu D, Tian G, et al. Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. Blood 2014; 124:2824-2833.
63. Müller N, Michen S, Tietze S, et al. NK cells modified with an EGFRvIII-specific chimeric antigen receptor to overexpress CXCR4 improves immunotherapy of CXCL12/SDF-1a-secreting glioblastoma. J Immunother 2015; 38:197- 210.
64. Jiang H, Zhang W, Shang P, et al. Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. Mol Oncol 2014; 8:297-310.
65. Schö nfeld K, Sahm C, Zhang C, et al. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. Mol Ther 2015; 23:330-338.
66. Töpfer K, Cartellieri M, Michen S, et al. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy. J Immunol 2015; 194:3201-3212.
67. Torikai H, Reik A, Liu PQ, et al. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimericantigen- receptor and eliminate expression of endogenous TCR. Blood 2012; 119:5697-5706.
68. Berdien B, Mock U, Atanackovic D, Fehse B. TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer. Gene Ther 2014; 21:539-548.
69. Poirot L, Philip B, Schiffer-Mannioui C, et al. Multiplex genome edited T-cell manufacturing platform for 'off-the-shelf' adoptive T-cell immunotherapies. Cancer Res 2015. [Epub ahead of print].
70. Mandal PK, Ferreira LMR, Collins R, et al. Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9. Cell Stem Cell 2014; 15:643-652.
71. Torikai H, Reik A, Soldner F, et al. Toward eliminating HLA class I expression to generate universal cells from allogeneic donors. Blood 2013; 122:1341- 1350.
72. Bridgeman JS, Hawkins RE, Bagley S, et al. The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex. J Immunol 2010; 184:6938-6949.
73. Bridgeman JS, Ladell K, Sheard VE, et al. CD3j-based chimeric antigen receptors mediate T cell activation via cis- And trans-signalling mechanisms: implications for optimization of receptor structure for adoptive cell therapy. Clin Exp Immunol 2014; 175:258-267..
74. Di Stasi A, Tey S-K, Dotti G, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 2011; 365:1673-1683.
75. Zhou X, Stasi ADi, Tey S, et al. Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. Blood 2014; 123:3895-3906.
76. Casucci M, Nicolis di Robilant B, Falcone L, et al. CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood 2013; 122:3461-3472.